Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3

Published 2019 View Full Article

  1. Home
  2. Publications
  3. Publication Search
  4. Publication Details
Title
Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3
Authors
Keywords
Buparlisib, Anthracyclines, AKR1C3, Multidrug resistance, Cancer, HCT116 cell line
Journal
CHEMICO-BIOLOGICAL INTERACTIONS
Volume 302, Issue -, Pages 101-107
Publisher
Elsevier BV
Online
2019-01-29
DOI
10.1016/j.cbi.2019.01.026

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started
Webinars Posters Questions Hubs Funding Journals Articles Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.